» Articles » PMID: 33193560

DeepLRHE: A Deep Convolutional Neural Network Framework to Evaluate the Risk of Lung Cancer Recurrence and Metastasis From Histopathology Images

Overview
Journal Front Genet
Date 2020 Nov 16
PMID 33193560
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

It is critical for patients who cannot undergo eradicable surgery to predict the risk of lung cancer recurrence and metastasis; therefore, the physicians can design the appropriate adjuvant therapy plan. However, traditional circulating tumor cell (CTC) detection or next-generation sequencing (NGS)-based methods are usually expensive and time-inefficient, which urge the need for more efficient computational models. In this study, we have established a convolutional neural network (CNN) framework called DeepLRHE to predict the recurrence risk of lung cancer by analyzing histopathological images of patients. The steps for using DeepLRHE include automatic tumor region identification, image normalization, biomarker identification, and sample classification. In practice, we used 110 lung cancer samples downloaded from The Cancer Genome Atlas (TCGA) database to train and validate our CNN model and 101 samples as independent test dataset. The area under the receiver operating characteristic (ROC) curve (AUC) for test dataset was 0.79, suggesting a relatively good prediction performance. Our study demonstrates that the features extracted from histopathological images could be well used to predict lung cancer recurrence after surgical resection and help classify patients who should receive additional adjuvant therapy.

Citing Articles

Predicting Postoperative Lung Cancer Recurrence and Survival Using Cox Proportional Hazards Regression and Machine Learning.

Pu L, Dhupar R, Meng X Cancers (Basel). 2025; 17(1).

PMID: 39796664 PMC: 11719023. DOI: 10.3390/cancers17010033.


Not seeing the trees for the forest. The impact of neighbours on graph-based configurations in histopathology.

Fourkioti O, De Vries M, Naidoo R, Bakal C BMC Bioinformatics. 2025; 26(1):9.

PMID: 39794715 PMC: 11724494. DOI: 10.1186/s12859-024-06007-x.


Next-generation lung cancer pathology: Development and validation of diagnostic and prognostic algorithms.

Kludt C, Wang Y, Ahmad W, Bychkov A, Fukuoka J, Gaisa N Cell Rep Med. 2024; 5(9):101697.

PMID: 39178857 PMC: 11524894. DOI: 10.1016/j.xcrm.2024.101697.


A new model using deep learning to predict recurrence after surgical resection of lung adenocarcinoma.

Kim P, Hwang H, Choi G, Sung H, Ahn B, Uh J Sci Rep. 2024; 14(1):6366.

PMID: 38493247 PMC: 10944489. DOI: 10.1038/s41598-024-56867-9.


Exploring the efficacy of artificial neural networks in predicting lung cancer recurrence: a retrospective study based on patient records.

Lorenc A, Romaszko-Wojtowicz A, Jaskiewicz L, Doboszynska A, Bucinski A Transl Lung Cancer Res. 2023; 12(10):2083-2097.

PMID: 38025814 PMC: 10654430. DOI: 10.21037/tlcr-23-350.


References
1.
Xu S, Lou F, Wu Y, Sun D, Zhang J, Chen W . Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients. Cancer Lett. 2015; 370(2):324-31. PMC: 7495502. DOI: 10.1016/j.canlet.2015.11.005. View

2.
Shackelford D, Abt E, Gerken L, Vasquez D, Seki A, Leblanc M . LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell. 2013; 23(2):143-58. PMC: 3579627. DOI: 10.1016/j.ccr.2012.12.008. View

3.
Esteva A, Kuprel B, Novoa R, Ko J, Swetter S, Blau H . Dermatologist-level classification of skin cancer with deep neural networks. Nature. 2017; 542(7639):115-118. PMC: 8382232. DOI: 10.1038/nature21056. View

4.
Shen D, Wu G, Suk H . Deep Learning in Medical Image Analysis. Annu Rev Biomed Eng. 2017; 19:221-248. PMC: 5479722. DOI: 10.1146/annurev-bioeng-071516-044442. View

5.
Fischer A, Jacobson K, Rose J, Zeller R . Hematoxylin and eosin staining of tissue and cell sections. CSH Protoc. 2011; 2008:pdb.prot4986. DOI: 10.1101/pdb.prot4986. View